following are the game changing steps for NNLX beginning August 18, 2014
this is all from mach10 post number 145 (look above, it is always there)
It has been almost four years since this was posted.
EXCERPT FROM POST 145
"Dr. Faro’s presentation led me to the conclusion that the N-Assay technology is a “game changer” across a range of distinct and dangerous conditions of bacterial infections. The identification of disease and the effective management of the individual patient is the role of the doctor. This suggests strongly that the N-Assay test represents the future direction of medical diagnosis and effective treatment through targeted and precise antibiotic infusion.
T he conclusion gained from Dr. Faro’s presentation is that there is no other methodology that can come close to matching the N-Assay technology on the significant range of diagnostic qualities detailed in 2013 by the Infectious Disease Society of America. The Society stated that a diagnostic test that could produce reliable results in one hour was needed to have a positive impact on patient care. The reliability of the test and its functional utility in a variety of important settings depended on the results being:
• Accurate
• Composed of heat stable reagents
• Having an extended shelf life
• Was portable
• Low cost relative to other methods
• Suitable for diagnosis of a broad range of clinical samples
• Required minimal technical skills
• Was rapid
• Sensitive
• Specific for each disease for which it was being used
• Provided on-demand individual testing rather than being delayed for large batched pools in order to reduce expense.
Dr. Faro indicated the current tests are simply not good enough to satisfy the full range of these critical criteria. They are also ill-suited to help deal with the array of emerging challenges related to infectious diseases. This includes the serious and growing problem of rampant antibiotic (AB) resistance caused by the almost automatic large scale generic infusion of antibiotic treatments that make up the treatment protocols in situations where a bacterial infection is diagnosed.
The rise in AB-resistant strains makes it essential that antibiotic overuse is avoided because a result of antibiotic overuse coupled with imprecisely targeted AB applications is the rapid growth in resistance by microbes that adapt to medicines to the point of rendering them ineffective. Dr. Faro commented on the fact that many doctors use antibiotics like they were “turning on a faucet”. This not only leads to a more rapid development of antibiotic resistance but entirely independent of the issue of AB resistance, the fact is that antibiotics are not simply benign substances. Antibiotics are quite dangerous drugs that can have important impacts on patient health.
An important aspect of Dr. Faro’s presentation is that the N-Assay test is machine-readable. He explained that the researchers modified the process in a way that they were able to shift to the ELISA format involving a simple plate reader. This resulted in being able to “achieve accurate test results in thirty (30) minutes rather than six hours. One breakthrough is that there is now no culture step required to achieve the rapid result.” Since it is color-coded and machine-readable ELISA eliminates inter-observer subjectivity and variability."
So we have a game changer that is four years old now and no one has the ability to get it used even once in the 16,000,000 US pregnancies in that time period?
Start with one test, get it approved, get it used, make it a game changer, get noticed, and move on to another test and start all over.
The fear is this will get passed up by better technology.
EXCERPT FROM POST 145
“NanoLogix received notification at the end of July of results for two time and temperature related tests that have been performed by a renowned independent third-party lab. In the first test, NanoLogix Tryptic Soy Agar (TSA) petri plates packed in the company's proprietary FlatPacks reached the 2-year point for room-temperature (RT) storage. The final test results for culturing of bacillus anthracis Ames (Anthrax) on the two-year-old plates were superior to the results obtained with competitor's one-week-old TSA plates, with NanoLogix's TSA plates performing as the equivalent to freshly poured plates. NanoLogix has elected to end the study, as the supply of FlatPacks that were furnished to the third-party lab two years ago predicated upon an initial four-month test for the DOD has been exhausted. The company recently completed its own testing of FlatPack packaged TSA petri plates stored for 3 years in cold storage with E-coli 0157 H7 as the test bacteria and observed results similar to those of the third-party lab 2 year RT test for Anthrax."
This testing proves longevity of the flat pack vs any other petri dish supplier. Why on earth have we not exploited this for all it is worth for the past four years to fill our coffers? This is a game changer and all we have is third party sales to create science kits for sale on Amazon. That is a huge business fail no matter how you look at it.
We don't even show our logo on that packaging. (I bought one to confirm).
Four years should be plenty enough time to start at least selling flat pack at a profit and getting noticed on the N-Assay.
Quit trying to hit the jackpot, it is not going to happen. Bring on some business partner and check the ego at the front desk.
this is all from mach10 post number 145 (look above, it is always there)
It has been almost four years since this was posted.
EXCERPT FROM POST 145
"Dr. Faro’s presentation led me to the conclusion that the N-Assay technology is a “game changer” across a range of distinct and dangerous conditions of bacterial infections. The identification of disease and the effective management of the individual patient is the role of the doctor. This suggests strongly that the N-Assay test represents the future direction of medical diagnosis and effective treatment through targeted and precise antibiotic infusion.
T he conclusion gained from Dr. Faro’s presentation is that there is no other methodology that can come close to matching the N-Assay technology on the significant range of diagnostic qualities detailed in 2013 by the Infectious Disease Society of America. The Society stated that a diagnostic test that could produce reliable results in one hour was needed to have a positive impact on patient care. The reliability of the test and its functional utility in a variety of important settings depended on the results being:
• Accurate
• Composed of heat stable reagents
• Having an extended shelf life
• Was portable
• Low cost relative to other methods
• Suitable for diagnosis of a broad range of clinical samples
• Required minimal technical skills
• Was rapid
• Sensitive
• Specific for each disease for which it was being used
• Provided on-demand individual testing rather than being delayed for large batched pools in order to reduce expense.
Dr. Faro indicated the current tests are simply not good enough to satisfy the full range of these critical criteria. They are also ill-suited to help deal with the array of emerging challenges related to infectious diseases. This includes the serious and growing problem of rampant antibiotic (AB) resistance caused by the almost automatic large scale generic infusion of antibiotic treatments that make up the treatment protocols in situations where a bacterial infection is diagnosed.
The rise in AB-resistant strains makes it essential that antibiotic overuse is avoided because a result of antibiotic overuse coupled with imprecisely targeted AB applications is the rapid growth in resistance by microbes that adapt to medicines to the point of rendering them ineffective. Dr. Faro commented on the fact that many doctors use antibiotics like they were “turning on a faucet”. This not only leads to a more rapid development of antibiotic resistance but entirely independent of the issue of AB resistance, the fact is that antibiotics are not simply benign substances. Antibiotics are quite dangerous drugs that can have important impacts on patient health.
An important aspect of Dr. Faro’s presentation is that the N-Assay test is machine-readable. He explained that the researchers modified the process in a way that they were able to shift to the ELISA format involving a simple plate reader. This resulted in being able to “achieve accurate test results in thirty (30) minutes rather than six hours. One breakthrough is that there is now no culture step required to achieve the rapid result.” Since it is color-coded and machine-readable ELISA eliminates inter-observer subjectivity and variability."
So we have a game changer that is four years old now and no one has the ability to get it used even once in the 16,000,000 US pregnancies in that time period?
Start with one test, get it approved, get it used, make it a game changer, get noticed, and move on to another test and start all over.
The fear is this will get passed up by better technology.
EXCERPT FROM POST 145
“NanoLogix received notification at the end of July of results for two time and temperature related tests that have been performed by a renowned independent third-party lab. In the first test, NanoLogix Tryptic Soy Agar (TSA) petri plates packed in the company's proprietary FlatPacks reached the 2-year point for room-temperature (RT) storage. The final test results for culturing of bacillus anthracis Ames (Anthrax) on the two-year-old plates were superior to the results obtained with competitor's one-week-old TSA plates, with NanoLogix's TSA plates performing as the equivalent to freshly poured plates. NanoLogix has elected to end the study, as the supply of FlatPacks that were furnished to the third-party lab two years ago predicated upon an initial four-month test for the DOD has been exhausted. The company recently completed its own testing of FlatPack packaged TSA petri plates stored for 3 years in cold storage with E-coli 0157 H7 as the test bacteria and observed results similar to those of the third-party lab 2 year RT test for Anthrax."
This testing proves longevity of the flat pack vs any other petri dish supplier. Why on earth have we not exploited this for all it is worth for the past four years to fill our coffers? This is a game changer and all we have is third party sales to create science kits for sale on Amazon. That is a huge business fail no matter how you look at it.
We don't even show our logo on that packaging. (I bought one to confirm).
Four years should be plenty enough time to start at least selling flat pack at a profit and getting noticed on the N-Assay.
Quit trying to hit the jackpot, it is not going to happen. Bring on some business partner and check the ego at the front desk.
4
